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Abstract
Background: Surveying deleterious variation in human populations is crucial for our understanding, diagnosis and
potential treatment of human genetic pathologies. A number of recent genome-wide analyses focused on the
prevalence of segregating deleterious alleles in the nuclear genome. However, such studies have not been
conducted for the mitochondrial genome.
Results: We present a systematic survey of polymorphisms in the human mitochondrial genome, including those
predicted to be deleterious and those that correspond to known pathogenic mutations. Analyzing 4458
completely sequenced mitochondrial genomes we characterize the genetic diversity of different types of single
nucleotide polymorphisms (SNPs) in African (L haplotypes) and non-African (M and N haplotypes) populations. We
find that the overall level of polymorphism is higher in the mitochondrial compared to the nuclear genome,
although the mitochondrial genome appears to be under stronger selection as indicated by proportionally fewer
nonsynonymous than synonymous substitutions. The African mitochondrial genomes show higher heterozygosity,
a greater number of polymorphic sites and higher frequencies of polymorphisms for synonymous, benign and
damaging polymorphism than non-African genomes. However, African genomes carry significantly fewer SNPs that
have been previously characterized as pathogenic compared to non-African genomes.
Conclusions: Finding SNPs classified as pathogenic to be the only category of polymorphisms that are more
abundant in non-African genomes is best explained by a systematic ascertainment bias that favours the discovery
of pathogenic polymorphisms segregating in non-African populations. This further suggests that, contrary to the
common disease-common variant hypothesis, pathogenic mutations are largely population-specific and different
SNPs may be associated with the same disease in different populations. Therefore, to obtain a comprehensive
picture of the deleterious variability in the human population, as well as to improve the diagnostics of individuals
carrying African mitochondrial haplotypes, it is necessary to survey different populations independently.
Reviewers: This article was reviewed by Dr Mikhail Gelfand, Dr Vasily Ramensky (nominated by Dr Eugene Koonin)
and Dr David Rand (nominated by Dr Laurence Hurst).
Background
The discovery of genetic variants associated with human
diseases is widely anticipated to be one of the stepping
stones leading to an era of personalized medicine. Hun-
dreds or even thousands of deleterious alleles segregate
in the human population [1-6] and contribute to a vast
diversity of disease conditions [7,8]. While most of them
are individually only slightly deleterious [2] taken
together an average genome carries several lethal
equivalents [6,9]. In principle, correlating genetic var-
iants to disease phenotypes in a sample of the human
population can reveal those variants that are likely to
contribute to disease. This is now routinely attempted
by genome-wide association studies (GWAS) [10-15] or
deleterious alleles predicted computationally on the
back of large-scale sequencing efforts [2,4]. However,
the success of GWAS in particular is dependent on
pathogenic polymorphisms segregating at relatively high
frequency in the population [12,13,16,17].
If common diseases are caused by common variants
then the polymorphisms implicated by GWAS are likely
to contribute to disease not only in the sample from the
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with the disease phenotype in the entire human popula-
tion. However, if common diseases in the human popu-
lation are caused by many rare variants then the
probability of discovery of these variants is low [12,13]
and different populations are likely to carry different
variants associated with one disease. Since a majority of
GWAS are performed within specific human popula-
tions [11,18,19] it is currently unclear if the disease var-
iants identified by a study as major contributors to a
specific disease in one population also contribute to the
same pathology in a different population.
To study the population-specific distributions of SNPs
we performed a comparison of variation encoded in the
mitochondrial genome in African and non-African
populations. We focused on the mitochondrial genome
for three reasons. First, the mitochondrial genome con-
tributes to dozens of genetic pathologies [8,20], second,
it has not been subject to a genome-wide survey of seg-
regating deleterious polymorphism and third, the diver-
sity of available completely sequenced mitochondrial
genomes allowed us to consider genomes from different
populations independently.
Methods
Genomic data
We obtained complete mitochondrial genome sequences
from GenBank using “complete genome AND Homo
sapiens [orgn]” as a query with “Mitochondrion and
Genomic DNA/RNA” selected in the Limits section of
the nucleotide search [21]. From this dataset we
excluded all genomes that were sequenced from an indi-
vidual with a known pathological condition as reflected
in the GenBank file leaving a total of 4458 genomes. We
identified 401 genomes as belonging to L haplotypes
(African) and 4057 genomes as belonging to the N or M
haplotype (non-African). Most of these genomes were
already assigned to these haplogroups. For the remain-
ing genomes we identified their haplogroup via BLAST
searches. We then made a multiple alignment of all gen-
omes using the MEGA 4 program package [22] with
manual curation. In this alignment we identify poly-
morphic sites, those sites in which more than one
nucleotide allele is found. Of these alleles we identify
the minor alleles, those that are the least frequent at a
polymorphic site, in protein coding, tRNA and rRNA
genes (Table 1).
Polymorphism data
Polymorphisms were classified for each protein coding
gene into “benign”, “possibly damaging” and “probably
damaging” using a standalone version of PolyPhen 2
[23] with the “possibly damaging” and “probably dama-
ging” categories pooled into one “damaging” category
for the purpose of our analysis. PolyPhen 2 normally
utilizes distant sequences for its prediction and does not
accept more than 1000 homologues in the alignment
used for classifying SNPs into the three categories. For
mitochondrial proteins more than 1000 homologues
were typically available and PolyPhen 2 did not always
select the most closely related orthologues for the align-
ment. We thus ran PolyPhen 2 using alignments of all
primate orthologous proteins. Although we treated
“probably damaging” and “possibly damaging” as a single
category, when both categories were compared our
results and conclusions remained the same (data not
shown). We estimated nucleotide diversity (π), which is
the average fraction of sites occupied by different alleles
in all pairwise sequence comparisons in the sample [24],
using MEGA 4 [22] with pairwise deletion and selecting
the Nei-Gojobori method to estimate the number of
substitutions between sequences. We obtained data on
Table 1 All polymorphism data from African and non-African populations
Number of variable sites Number of minor alleles
SNP Category Total African Non-African African Non-African
Synonymous 2574 (67.1%) 792 (71.0%) 2422 (67.3%) 8614 39183
- Four fold 1177 (45.7%) 419 (53.0%) 1274 (52.6%) 4877 20284
Nonsynonymous 1263 (32.9%) 323 (29.0%) 1178 (32.7%) 2942 15688
- Unknown 4 (0.3%) 1 (0.3%) 4 (0.3%) 5 51
- Benign 922 (73.0%) 263 (81.4%) 865 (73.4%) 2727 14611
- Damaging 338 (26.7%) 59 (18.3%) 309 (26.3%) 210 1025
Pathogenic total 87 27 85 83 1259
- Coding regions 55 19 53 56 956
- tRNAs 25 7 25 26 177
- rRNAs 7 1 7 1 126
Some polymorphic sites were shared between the two populations, leading to fewer polymorphic sites in the total category than just the sum of polymorphic
sites from each population.
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[25] and to reduce the possibility of erroneous patho-
genic mutations affecting our results we excluded all
categories of pathogenic mutations other than
“Reported” and “Confirmed” as well as all mutations
reported by [26]. Mann-Whitney U-test was applied to
test the statistical significance of the differences reported
in the tables, with the values in Table 3 obtained by the
Monte Carlo sampling by 1000 replicates of 401
sequences selected from the non-African genomes for
the analysis. As there is a large difference between the
African and non-African sample sizes in our dataset we
applied a Monte-Carlo technique to obtain sample-inde-
pendent estimates when required. Values in Tables 2-4
are reported with standard errors.
Results
Differences in the level of polymorphism among the
African and non-African population have been studied
extensively for the nuclear genome [27-31]. Thus, some
of the data reported here, and their interpretation, are
analogous to those reported for the nuclear genome. In
agreement with previously published data [27-31] the
African genomes showed higher nucleotide diversity, π,
at all classes of sites compared with non-African gen-
omes (Table 2), with this difference being less pro-
nounced for nonsynonymous SNPs (nSNPs). The
nucleotide diversity obtained for the mitochondrial
genes was higher than that for equivalent sites in the
nuclear genome with mitochondrial synonymous diver-
sity (πs) ~2.5 fold and mitochondrial nonsynonymous
diversity (πn) ~6.5-8.5 fold higher than the estimates
from the nuclear genome (Table 1 from ref. [1]), which
is consistent with a higher rate of mutation in the
mitochondrial genome [32] that allowed nucleotide
diversity to accumulate faster after the recent population
expansion [27-31]. The larger difference between πs and
πn indicates that nonsynonymous sites are under stron-
ger selection in the mitochondrial genome [33,34]. How-
ever, while the difference in mitochondrial and nuclear
πs was similar for African and non-African populations
t h ed i f f e r e n c ef o rπn was lower for the non-African
population (8.5 fold in the African and 6.5 for non-Afri-
can genomes), indicating that negative selection against
mitochondrial nonsynonymous alleles has been relaxed
in the non-African population.
We used PolyPhen 2 [23] to predict the fitness impact
of nSNPs classifying each nSNP as either “benign” or
“damaging” (see Methods). The damaging category must
be enriched for SNPs that are likely to be deleterious,
while the benign category includes likely neutral variants
[2,4,23], as is indicated by a 2-5 fold lower average fre-
quency of SNPs labelled as damaging compared to the
f r e q u e n c yo ft h o s ee s t i m a t e dt ob eb e n i g n( T a b l e3 ) .
Consistent with our data on nucleotide diversity, we
found alleles in the African population to have a higher
average frequency than in the non-African population.
Congruent results were obtained when measuring the
average number of minor alleles per genome, with Afri-
can genomes carrying approximately twice the number
of minor alleles, with this difference being similar for
benign and damaging SNPs (Table 4).
Levels of polymorphism are influenced by mutation,
selection and genetic drift. All three of these factors
necessarily need to be invoked to explain all of the
observations mentioned above. First, the higher πn and
πs in the mitochondrial relative to the nuclear genome
is consistent with a higher rate of mutation in the mito-
chondrial genome [32]. Second, the larger difference
between πn and πs in the mitochondrial genome relative
to the nuclear genome indicates that nonsynonymous
sites in the organelle are under stronger negative selec-
tion. Finally, a largely similar difference in πn and πs
and in the average number of minor alleles per genome
b e t w e e nt h eA f r i c a na n dn o n - A f r i c a np o p u l a t i o n s
Table 3 Average frequency of minor alleles
SNP Category African (401 genomes) Non-African (4057genomes) Non-African (Monte-Carlo
sampling of 401 genomes)
U-test p-value
Synonymous 0.027 ± 0.003 0.0040 ± 0.0004 0.011 ± 4 × 10
-6 7.9 × 10
-6
- Four fold 0.029 ± 0.004 0.0039 ± 0.0005 0.011 ± 4 × 10
-6 2.4 × 10
-6
Nonsynonymous 0.023 ± 0.005 0.0033 ± 0.0006 0.011 ± 4 × 10
-6 1.5 × 10
-6
- Benign 0.026 ± 0.006 0.0042 ± 0.0008 0.012 ± 5 × 10
-6 1.0 × 10
-6
- Damaging 0.0089 ± 0.009 0.00082 ± 9 × 10
-5 0.0038 ± 3 × 10
-6 1.7 × 10
-3
Pathogenic total 0.0077 ± 0.003 0.0037 ± 0.001 0.0084 ± 8 × 10
-6 1.0 × 10
-6
- Coding regions 0.0074 ± 0.003 0.0044 ± 0.001 0.0095 ± 1 × 10
-5 1.0 × 10
-6
Table 2 π for different types of sites
SNP Category African Non-African U-test p-value
Synonymous 0.010 ± 1 × 10
-5 0.0054 ± 1 × 10
-6 <1×1 0
-5
- Four fold 0.0089 ± 1 × 10
-5 0.0044 ± 8 × 10
-7 <1×1 0
-5
Nonsynonymous 0.0011 ± 2 × 10
-6 0 . 0 0 0 8 7±1×1 0
-7 <1×1 0
-5
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shaping the difference between the levels of polymorph-
ism in African and non-African populations than differ-
ences in selection pressure. However, a slight difference
in the strength of negative selection in the African ver-
sus non-African population is also consistent with these
and nuclear data [4].
Using data from MitoMap [25] we then identified
those minor alleles among our dataset that are known
to contribute to genetic pathologies. The pathogenic
SNPs show the opposite trends when comparing African
and non-African population than all other types of poly-
morphism. Pathogenic SNPs have a higher frequency
and density in the non-African population (Table 3 and
4). This difference is also pronounced when comparing
pathogenic and damaging SNPs (Figure 1 and 2).
Discussion
At first glance the higher number and frequency of patho-
genic SNPs in genomes from the non-African population
can be explained by a relaxation of selection in the Out-
of-Africa population [4,28,35]. However, three lines of
Table 4 Average number of minor alleles per genome
SNP Categories African (401 genomes) Non-African (4057 genomes) U-test p-value
Synonymous 21.5 ± 0.5 9.7 ± 0.1 2.2 × 10-6
- Four fold 12.2 ± 0.3 5.0 ± 0.06 2.2 × 10-6
Nonsynonymous 7.3 ± 0.2 3.9 ± 0.04 2.2 × 10-6
- Benign 6.8 ± 0.2 3.6 ± 0.03 2.2 × 10-6
- Damaging 0.53 ± 0.04 0.25 ± 0.009 2.2 × 10-6
Pathogenic total 0.21 ± 0.02 0.31 ± 0.008 1.3 × 10-6
- Coding Regions 0.14 ± 0.02 0.24 ± 0.007 1.6 × 10-3
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Figure 1 Ratio of the average number of minor alleles per genome of the two populations. For each category of polymorphisms we
obtained the ratio by dividing the average number of minor alleles per genome in the non-African population by the average number of minor
alleles per genome in the African population. Data shown with s.e.m.
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trend of SNPs in the damaging category (Table 3 and 4)
suggests that, overall, the difference in strength of selec-
tion between the African and non-African populations is
relatively minor. Second, data from the nuclear genome
confirm our results that there is only a minor difference in
selection between the African and non-African popula-
tions [4]. Finally, such subtle changes in selection pressure
between African and non-African populations are
expected to affect slightly deleterious alleles to a much lar-
ger extent than strongly deleterious alleles [4,36]. The
pathogenic SNPs almost certainly belong to a more dele-
terious category of SNPs than all damaging SNPs and,
therefore, relaxed selection cannot account for the
observed differences in these two categories of SNPs
between the African and the non-African populations.
The most parsimonious explanation for the observed
pattern is a systematic ascertainment bias of pathogenic
mutations leading to mitochondrial diseases in the non-
African populations. Such a bias easily explains a higher
number of pathogenic SNPs found in the non-African
population (Figure 1) as well as their higher frequency
relative to the damaging category (Figure 2). The presence
of such a bias in genetic studies implies that we cannot get
a full picture of the deleterious variability in the overall
human population until such polymorphisms are compre-
hensively surveyed in African populations [35].
A wave of GWAS followed the suggestion that com-
mon diseases are caused by common pathogenic variants
[16,17]. The present data show that knowledge of specific
pathogenic variants from one population does not lead to
a proportional discovery of pathogenic mutations in
another, at least in the mitochondrial genome. Thus, it is
likely that to advance the scope of personalized medicine
the identification of pathogenic variants, especially in
relation to GWAS, must be performed independently
across all of human populations. Also, GWAS of specific
human populations are likely to have more power for
detecting disease-causing variants than studies with a
sample of a mixture of humans from the total population.
Conclusions
Our survey of the genome-wide variability in the mito-
chondrial human genome revealed three distinct
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Figure 2 Ratio of the average frequency of segregating minor alleles of the two populations. For each category of polymorphisms we
obtained the ratio by dividing the average frequency of segregating minor alleles per genome in the non-African population by the average
frequency of minor alleles per genome in the African population. Data shown with s.e.m.
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Page 5 of 7patterns. First, selection against nonsynonymous alleles
is stronger in the mitochondrial genome than in the
nuclear one. Thus, the higher nucleotide diversity in the
mitochondrial genome is likely explained by a higher
mutation rate and not relaxation of selection. Second, a
similar difference in the nucleotide density of all classes
of SNPs implies that genetic drift is at present a stron-
ger factor than selection in shaping differences in varia-
bility of the mitochondrial genome between African and
non-African populations. Finally, the higher density of
pathogenic SNPs in the non-African population is likely
to be a result of an ascertainment bias in favour of dis-
covering common pathogenic SNPs in the non-African
population. Given the non-African focus of many
GWAS [11,18,19] it is likely that this bias also affects
our understanding of human pathologies with a nuclear-
based genetic component.
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